Evrysdi (risdiplam) Treatment for Spinal Muscular Atrophy
Evrysdi is a survival of motor neuron 2 (SMN2) splicing modifier approved by the US Federal Drug Administration (FDA) for children greater than 2 months of age with spinal muscular atrophy (SMA).
Evrysdi frequently asked questions:
Is my child eligible for Evrysdi treatment? According to hospital protocol and FDA regulation, your child must have the survival motor neuron 1 (SMN1) genetic mutations that causes SMA. Prior to starting therapy, this much be confirmed with genetic testing results.
According to the FDA, patients with all types of SMA greater than 2 months of age are eligible. At Children’s of Alabama we are currently dosing pediatric patients and accepting new referrals.
How is Evrysdi given to patients? Evrysdi is taken orally once daily after a meal at approximately the same time each day. Recommended dosage is determined per your doctor by age and body weight.
Will my child’s insurance cover Evrysdi treatment? In Alabama, insurance coverage varies based on your plan. We recommend talking to your insurance provider as well as our medical team to determine the best course of action. We work with each insurance provider and family to obtain prior authorization before Evrysdi can be administered. Along with the Evrysdi medication, patients and families could incur costs from routine assessment, laboratory testing, and clinic appointments related to SMA.
How do I get this treatment started for my child? All patients interested in Evrysdi must have established and ongoing care here at Children’s of Alabama. Our team will work with each family through the prior authorization process prior to scheduling your child to receive the medication from the pharmacy. For questions or interest regarding Evrysdi please call our MDA Care Center Coordinator, Shelley Coskery, at 205-638-2007.
For additional information, please visit the Genentech official website Evrysdi.com